影响皮肤经肝胆道排水治疗恶性胆道阻塞的患者生存的因素
Y Duzkopru1, T Eren, A Kocanoglu
1Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey. yakupduzkopru@gmail.com.
European review for medical and pharmacological sciences
|March 4, 2024
概括
通过皮肤透肝胆道排水 (PTBD) 治疗恶性胆道阻塞 (MBO) 的预后因素被确定. 多学科决策应考虑ECOGPS,并发症,白蛋白和先前的化疗状态,以获得更好的患者结果.
科学领域:
- 干预性放射学 干预性放射学
- 在瘤学瘤学.
- 胆汁干预 胆汁干预
背景情况:
- 恶性胆道阻塞 (MBO) 的管理通常涉及息性排水.
- 对于MBO而言,皮肤穿越肝胆道排水 (PTBD) 的生存益处受到争议.
- 确定预后因素对于优化患者护理至关重要.
研究的目的:
- 调查MBO接受PTBD的患者的独立预后因素.
- 在这个患者队列中确定整体生存 (OS) 的预测因素.
主要方法:
- 对152名为MBO接受PTBD的患者进行了回顾性分析.
- 实验室值根据中位数值进行二分化.
- 总体存活率从PTBD到死亡或最后的随访计算.
- 进行了单变量和多变量考克斯回归分析.
主要成果:
- 平均整体生存时间为71天.
- 多变量分析确定了并发症,ECOG PS,PTBD前白蛋白,PTBD后AST,化疗无效状态和PTBD后化疗作为独立的预后因素.
- 一年后的OS率为13%.
结论:
- 在MBO预后中,ECOG PS,并发症,白蛋白水平和先前的化疗状态是关键因素.
- 在预后不佳的MBO中,对PTBD的多学科决策至关重要.
- 这些因素有助于为MBO患者定制治疗策略.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
01:20Cholecystitis
32
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
32